A software platform developed by NeuraLight to evaluate eye movement abnormalities could soon be used to help assess amyotrophic lateral sclerosis (ALS), according to new research published in the Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration journal. NeuraLight announced that the use of the platform correlated with current gold-standard clinical assessments, making it a viable adjunct assessment tool.
ALS is an incurable progressive neurodegenerative disease also known as Lou Gehrig’s Disease . Although few pharmaceutical treatments are currently available, there is increasing innovation in the medical device space to help manage the disease. Artificial intelligence is also being used to help ALS patients communicate and robotic braces have been developed to aid movement.
Based on data from the research paper, NeuraLight’s oculometric platform could be used as an assessment tool for ALS patients. It would be used in tandem with the ALSFRS-R – the gold standard clinical assessment scale for ALS. The study demonstrated the importance of oculometric measures as an objective biomarker. The use of oculometric measures in drug trials could help streamline drug development and patient clinical status efficiency.
Professor Vivian Drory, director of the Neuromuscular Diseases Unit at Tel Aviv Sourasky Medical Center, and lead investigator of the study, said the technology can be implemented in clinical trials and also as part of a routine assessment for ALS patients.
“In recent years, we’ve seen a positive trend towards a more personalised clinical approach in the diagnosis and assessment of ALS patients, among them the use of different objective biomarkers,” said Drory.
“We used NeuraLight’s software-based platform to extract different oculometric measures as objective measurements for ALS patients. We found a correlation between the eye movement data retrieved using NeuraLight’s technology and motor disability as measured by ALSFRS-R.”